|
|
|
|
|
 |
|
|
| |
Merck’s Cholesterol Drugs—Low Hanging Fruit?
 Email  Printer-Friendly |
|
Naomi Freundlich,
The Century Foundation,
11/30/2009
|
|
|
|
If an expensive, name-brand cholesterol drug costs four times more than a generic but provides no clear clinical benefit, why do insurers—both public and private—continue to pay for it? The answer, in the case of Vytorin, a combination of two drugs designed to lower LDL or bad cholesterol, is that the influence of big Pharma in maintaining the status quo—even when unsupported by evidence—remains a formidable barrier. Continue Reading on the Taking Note Blog. |
|
| |
|
|
Copyright 2008 The Century Foundation. Privacy Policy
NY Office: 41 East 70th Street—New York, New York—10021—Phone:212-535-4441—212-879-9197
DC Office: 1333 H Street, NW—10th Floor— Washington, D.C.
20005— Phone: 202-387-0400— Fax: 202-483-9430 |
|
|
|
Taking Note
